Turkiye Klinikleri Journal of Dermatology

.: REVIEW
İzotretinoinin Akne Dışı Kullanım Alanları: Geleneksel Derleme
Uses of Isotretinoin Other Than Acne: Traditional Review
Beliz BAYINDIRa , Hatice ŞANLIa
aAnkara Üniversitesi İbn-i Sina Hastanesi, Deri ve Zührevi Hastalıkları Kliniği, Ankara, Türkiye
Turkiye Klinikleri J Dermatol. 2023;33(2):73-82
doi: 10.5336/dermato.2023-95935
Article Language: TR
Full Text
ÖZET
 İzotretinoin, retinolden türetilen sentetik bir retinoiddir. Sistemik izotretinoin, yıllardır şiddetli akne vulgaris tedavisinde kullanılmaktadır. İzotretinoin, akne vulgarisin 4 etiyopatogenik faktörüne tek başına etki eden tek ilaçtır. Bunun yanı sıra sistemik izotretinoin immünomodülatör, antiinflamatuar, anti-tümör, anti-anjiyogenik etkileri ile akne vulgaris dışındaki birçok dermatolojik hastalıkta da kullanılabilmektedir. İzotretinoin; immünomodülatör etkisi ile T ve B lenfositler üzerine, antiinflamatuar etkisi ile polimorfonükleer lökositler üzerine, anti-tümör etkisi ile gen ekspresyonu üzerine, anti-anjiyogenik etkisi ile de endotelyal hücreler ve keratinositler üzerine etki etmektedir. Sistemik izotretinoinin son yıllarda akne dışındaki dermatolojik hastalıklarda kullanımı giderek artmaktadır. İzotretinoinin akne dışındaki temel kullanım alanları; inflamatuar dermatozlar (rozase, psöriyazis, hidradenitis süpürativa, pityriazis rubra pilaris), enfeksiyöz hastalıklar (yassı siğiller, kondiloma akuminata), sebase bez patolojileri (sebore, seboreik dermatit, sebase hiperplazi, sebase adenom), skatrisyel alopesiler (dissekan selülit, folikülitis dekalvans, frontal fibrozan alopesi), non-melanom deri kanserleri (aktinik keratoz, skuamöz hücreli karsinom, bazal hücreli karsinom, kutanöz T hücreli lenfoma, kseroderma pigmentozum, Gorlin Goltz sendromu, epidermodisplazya verrüsiformis), kozmetik dermatoloji (fotoyaşlanma, rinoplasti operasyonu sonrası) ve keratinizasyon bozukluklarıdır (iktiyozlar, eritrokeratodermalar, palmoplantar keratodermalar, Darier hastalığı, Hailey-Hailey hastalığı). Bunlar dışında da birçok dermatolojik hastalıkta izotretinoinin faydalı olduğunu belirten vaka raporları ve serileri mevcuttur. Ancak izotretinoinin bu dermatolojik hastalıkların çoğunda tam olarak nasıl ve ne zaman kullanılabileceğini netleştirmek için daha fazla çalışmaya ihtiyaç vardır.

Anahtar Kelimeler: İzotretinoin; tedavi
ABSTRACT
 Isotretinoin is a synthetic retinoid derived from retinol. Systemic isotretinoin has been used for years in the treatment of severe acne vulgaris. Isotretinoin is the only drug that acts alone on the 4 etiopathogenic factors of acne vulgaris. In addition, systemic isotretinoin can be used in many dermatological diseases other than acne vulgaris with its immunomodulatory, anti-inflammatory, antitumor, anti-angiogenic effects. It acts on T and B lymphocytes with its immunomodulatory effect, on polymorphonuclear leukocytes with its anti-inflammatory effect, on gene expression with its anti-tumor effect and on endothelial cells and keratinocytes with its anti-angiogenic effect. The use of systemic isotretinoin in dermatological diseases other than acne has been increasing in recent years. The main uses of isotretinoin other than acne; inflammatory dermatoses (rosacea, psoriasis, hidradenitis suppurativa, pityriasis rubra pilaris), infectious diseases (flat warts, condyloma acuminata), sebaceous gland pathologies (seborrhea, seborrheic dermatitis, sebaceous hyperplasia, sebaceous adenoma), cicatricial alopecias (dissecting cellulitis, folliculitis decalvans, frontal fibrosing alopecia), non-melanoma skin cancers (actinic keratosis, squamous cell carcinoma, basal cell carcinoma, cutaneous Tcell lymphoma, xeroderma pigmentosum, Gorlin Goltz syndrome, epidermodysplasia verrusiformis), cosmetic dermatology (photoaging, after rhinoplasty operation) and keratinization disorders (ichthyoses, erythrokeratodermas, palmoplantar keratodermas, Darier's disease, Hailey-Hailey disease). Apart from these, there are case reports and series indicating that isotretinoin is beneficial in many dermatological diseases. However, more studies are needed to clarify exactly how and when isotretinoin can be used in most of these dermatological conditions.

Keywords: İsotretinoin; therapy
REFERENCES:
  1. Akyol M, Ozçelik S. Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol. 2005;6(3):175-84. [Crossref]  [PubMed] 
  2. Bagatin E, Costa CS, Rocha MADD, Picosse FR, Kamamoto CSL, Pirmez R, et al. Consensus on the use of oral isotretinoin in dermatology-Brazilian Society of Dermatology. An Bras Dermatol. 2020;95 Suppl 1(Suppl 1):19-38. [Crossref]  [PubMed]  [PMC] 
  3. Forbat E, Ali FR, Al-Niaimi F. Dermatological indications for the use of isotretinoin beyond acne. J Dermatolog Treat. 2018;29(7):698-705. [Crossref]  [PubMed] 
  4. Abdelmaksoud A, Lotti T, Anadolu R, Goldust M, Ayhan E, Dave DD, et al. Low dose of isotretinoin: a comprehensive review. Dermatol Ther. 2020;33(2):e13251. [Crossref]  [PubMed] 
  5. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134(7):884-5. [Crossref]  [PubMed] 
  6. Sbidian E, Vicaut É, Chidiack H, Anselin E, Cribier B, Dréno B, et al. A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol. 2016;136(6):1124-9. [Crossref]  [PubMed] 
  7. Hofer T. Continuous 'microdose' isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29(2):204-5. [Crossref]  [PubMed] 
  8. Walsh RK, Endicott AA, Shinkai K. Diagnosis and treatment of rosacea fulminans: a comprehensive review. Am J Clin Dermatol. 2018;19(1):79-86. [Crossref]  [PubMed] 
  9. Rallis E, Korfitis C. Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature. J Cutan Med Surg. 2012;16(6):438-41. [Crossref]  [PubMed] 
  10. Wee JS, Tan KB. Phymatous rosacea presenting with leonine facies and clinical response to isotretinoin. Australas J Dermatol. 2017;58(1):72-3. [Crossref]  [PubMed] 
  11. Schaller M, Almeida LM, Bewley A, Cribier B, Dlova NC, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465-71. [Crossref]  [PubMed] 
  12. Andrade FMX, Picosse FR, Cunha LPD, Valente CM, Bezerra FM, Miot H, et al. Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline. Arq Bras Oftalmol. 2020;83(2):109-12. [Crossref]  [PubMed] 
  13. Huang CM, Kirchhof MG. A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology. 2017;233(2-3):120-5. [Crossref]  [PubMed] 
  14. Patel N, McKenzie SA, Harview CL, Truong AK, Shi VY, Chen L, et al. Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatolog Treat. 2021;32(4):473-5. [Crossref]  [PubMed] 
  15. Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17(3):243-59. [Crossref]  [PubMed] 
  16. Yang TH, Lee TH, Huang YC. Oral isotretinoin for treating mucocutaneous human papillomavirus infections: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2019;85(6):569-77. [Crossref]  [PubMed] 
  17. Yildirim M, Inaloz HS, Baysal V, Kesici D, Candir O. A case of condyloma acuminatum treated successfully with low-dose isotretinoin and interferon. Int J Clin Pract. 2004;58(9):889-91. [Crossref]  [PubMed] 
  18. Herold M, Nielson C, Longo MI. Isotretinoin and candida immunotherapy for recalcitrant warts in solid organ transplant recipients. Dermatol Ther. 2019;32(2):e12803. [Crossref]  [PubMed] 
  19. de Souza Leão Kamamoto C, Sanudo A, Hassun KM, Bagatin E. Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. Int J Dermatol. 2017;56(1):80-5. [Crossref]  [PubMed] 
  20. Liu YS, Cheng YP, Liu CI, Yang CY, Yang CY. Presenile diffuse familial sebaceous hyperplasia successfully treated with low-dose isotretinoin: a report of two cases and review of the published work. J Dermatol. 2016;43(10):1205-8. [Crossref]  [PubMed] 
  21. Jung HY, Kim M, Cho BK, Park HJ. A case of cyclosporine-induced sebaceous hyperplasia in a renal transplant patient successfully treated with isotretinoin. Ann Dermatol. 2016;28(2):271-2. [Crossref]  [PubMed]  [PMC] 
  22. Mutizwa MM, Berk DR. Dichotomous long-term response to isotretinoin in two patients with fordyce spots. Pediatr Dermatol. 2014;31(1):73-5. [Crossref]  [PubMed] 
  23. Pedrosa AF, Duarte AF, Haneke E, Correia O. Yellow facial papules associated with frontal fibrosing alopecia: a distinct histologic pattern and response to isotretinoin. J Am Acad Dermatol. 2017;77(4):764-6. [Crossref]  [PubMed] 
  24. Imhof R, Tolkachjov SN. Optimal management of frontal fibrosing alopecia: a practical guide. Clin Cosmet Investig Dermatol. 2020;13:897-910. [Crossref]  [PubMed]  [PMC] 
  25. Babahosseini H, Tavakolpour S, Mahmoudi H, Balighi K, Teimourpour A, Ghodsi SZ, et al. Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. J Dermatolog Treat. 2019;30(6):598-604. [Crossref]  [PubMed] 
  26. DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol. 1998;39(2 Pt 3):S82-5. [Crossref]  [PubMed] 
  27. Lens M, Medenica L. Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert Opin Pharmacother. 2008;9(8):1363-74. [Crossref]  [PubMed] 
  28. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32(4):562-8. [Crossref]  [PubMed] 
  29. Ianhez M, Pinto SA, Miot HA, Bagatin E. A randomized, open, controlled trial of tretinoin 0.05% cream vs. low-dose oral isotretinoin for the treatment of field cancerization. Int J Dermatol. 2019;58(3):365-73. [Crossref]  [PubMed] 
  30. Tauber M, Monsel G, Bonnecarrère L, Battistella M, Cordel N, Honein C, et al. Unresectable perineal cuniculatum carcinoma: partial remission using systemic isotretinoin and interferon-α2a therapy. Acta Derm Venereol. 2014;94(6):721-2. [Crossref]  [PubMed] 
  31. Sazgar AA, Majlesi A, Shooshtari S, Sadeghi M, Sazgar AK, Amali A. Oral isotretinoin in the treatment of postoperative edema in thick-skinned rhinoplasty: a randomized placebo-controlled clinical trial. Aesthetic Plast Surg. 2019;43(1):189-95. [Crossref]  [PubMed] 
  32. Cobo R, Vitery L. Isotretinoin use in thick-skinned rhinoplasty patients. Facial Plast Surg. 2016;32(6):656-61. [Crossref]  [PubMed] 
  33. Rabello-Fonseca RM, Azulay DR, Luiz RR, Mandarim-de-Lacerda CA, Cuzzi T, Manela-Azulay M. Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication. J Eur Acad Dermatol Venereol. 2009;23(2):115-23. [Crossref]  [PubMed] 
  34. Bravo BS, Azulay DR, Luiz RR, Mandarim-De-Lacerda CA, Cuzzi T, Azulay MM. Oral isotretinoin in photoaging: objective histological evidence of efficacy and durability. An Bras Dermatol. 2015;90(4):479-86. [Crossref]  [PubMed]  [PMC] 
  35. Bagatin E, Guadanhim LR, Enokihara MM, Sanudo A, Talarico S, Miot HA, et al. Low-dose oral isotretinoin versus topical retinoic acid for photoaging: a randomized, comparative study. Int J Dermatol. 2014;53(1):114-22. [Crossref]  [PubMed] 
  36. Digiovanna JJ, Mauro T, Milstone LM, Schmuth M, Toro JR. Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther. 2013;26(1):26-38. [Crossref]  [PubMed]  [PMC] 
  37. Pasmatzi E, Georgiou S, Monastirli A, Tsambaos D. Temporary remission of disseminated granuloma annulare under oral isotretinoin therapy. Int J Dermatol. 2005;44(2):169-71. [Crossref]  [PubMed] 
  38. D'Erme AM, Milanesi N, Difonzo EM, Lotti T, Gola M. Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option. Dermatol Ther. 2012;25(3):281-2. [Crossref]  [PubMed] 
  39. Handler HL. Isotretinoin for oral lichen planus. J Am Acad Dermatol. 1984;10(4):674. [Crossref]  [PubMed] 
  40. Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis. 1985;35(4):385-6, 390-1, 393. [PubMed] 
  41. Camisa C, Allen CM. Treatment of oral erosive lichen planus with systemic isotretinoin. Oral Surg Oral Med Oral Pathol. 1986;62(4):393-6. [Crossref]  [PubMed] 
  42. Muthu SK, Narang T, Saikia UN, Kanwar AJ, Parsad D, Dogra S. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016;55(9):1048-54. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com